Dr. Emil Toma is a clinical professor in the Department of Microbiology, Immunology, and Infectious Diseases at the Centre hospitalier de l’Université de Montréal. He works out of the Hôtel-Dieu campus. He completed his Doctorate in Science in microbiology with a specialization in infectious diseases at the University of Bucharest, Romania.

His research interests include therapeutic strategies for HIV infection, metabolic and hormonal issues stemming from antiretroviral therapy, and the effects of antiretroviral therapy on the metabolism of retinoic acids. He took part in the development of a “boosted-reverse transcriptase inhibitor”, which is now patented in the USA, Australia, and Canada.

He has contributed to several CTN research publications, and has published more than 138 papers in peer-reviewed journals, five books, and has contributed to at least eight other books. He was also the principal investigator in CTN 140, which was an early proof-of-concept study which tested if intensification of ART in combination with a therapeutic vaccine (Remune) would allow participants to control HIV without ART.